The court’s injunction prevents generic manufactures to distribute generic Pulmicort Respules, until it reaches a final decision on AstraZeneca’s appeal of the verdict of the US District Court for the ...
On 20 May 2009, the US District Court for the District of New Jersey granted AstraZeneca's request for an injunction barring Apotex (Apotex, Inc. and Apotex Corp.) from launching a generic version of ...
AstraZeneca today announced that the United States District Court for the District of New Jersey ruled that AstraZeneca's US Patent No. 6,598,603 ("the '603 patent"), protecting PULMICORT RESPULES in ...
Recently, United States District Court for the District of New Jersey dealt a blow to AstraZeneca (AZN) when it ruled that a patent (6,598,603) protecting Pulmicort Respules (budesonide inhalation ...
PARSIPPANY, N.J., April 1, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today confirmed that the United States District Court for the District of New Jersey has ruled that Actavis' generic version ...
Budesonide (micronized) 0.25mg/2mL, 0.5mg/2mL, 1mg/2mL; susp for inhalation. Pulmicort Respules is supplied in sealed aluminum foil envelopes containing one plastic strip of five single-dose Respules ...
A US court has confirmed that a key patent on AstraZeneca’s Pulmicort Repsules is invalid and Actavis has immediately launched its version of the asthma drug. A US court has confirmed that a key ...
San Diego, Calif. – May 24, 2005 – Young children who are adherent with asthma controller therapies overall, and specifically PULMICORT RESPULES® (budesonide inhalation suspension), have lower ...
A week is not normally a long time in patent disputes but it has been long enough for AstraZeneca and Teva to settle their difference over a generic version of the former’s asthma drug Pulmicort. A ...
On 19 November 2008, AstraZeneca was granted a Temporary Restraining Order (TRO) by the United States District Court for the District of New Jersey, halting sales of Teva's budesonide inhalation ...
Sept. 28, 2005 ( updated Oct. 6, 2005) -- The U.S. Food and Drug Administration (FDA) approved safety labeling revisions in June to advise that doxercalciferol dose reductions are recommended in ...
Research and Markets: Investigation Report on China's Budesonide (Pulmicort Respules) Market to 2018
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/5rp48m/investigation) has announced the addition of the "Investigation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results